R R

What Is Ojjaara?

Ojjaara is a prescription medication containing momelotinib, an oral kinase inhibitor used to treat certain adults with myelofibrosis and anemia. It is approved for intermediate- or high-risk primary myelofibrosis and secondary myelofibrosis developing after polycythemia vera or essential thrombocythemia. Myelofibrosis is a bone marrow disorder that interferes with normal blood cell production. Ojjaara targets signaling pathways involved in the disease and can help improve anemia-related outcomes and other disease symptoms.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Ojjaara?

Ojjaara is a prescription medication containing momelotinib, an oral kinase inhibitor used to treat certain adults with myelofibrosis and anemia. It is approved for intermediate- or high-risk primary myelofibrosis and secondary myelofibrosis developing after polycythemia vera or essential thrombocythemia. Myelofibrosis is a bone marrow disorder that interferes with normal blood cell production. Ojjaara targets signaling pathways involved in the disease and can help improve anemia-related outcomes and other disease symptoms.

read more about ojjaara ...

Copy this HTML:

Copy HTML Copied!

How Does Ojjaara Work?

Ojjaara inhibits Janus kinase 1 and 2, known as JAK1 and JAK2, as well as activin A receptor type 1, or ACVR1. Abnormal JAK signaling contributes to inflammatory activity and abnormal blood cell production in myelofibrosis. Inhibition of ACVR1 can reduce hepcidin production, a hormone involved in regulating iron availability. These actions can help improve anemia and control certain myelofibrosis symptoms. Ojjaara does not cure the underlying bone marrow disease.

Who Can Receive Ojjaara Treatment?

Ojjaara is approved for adults with intermediate- or high-risk myelofibrosis who also have anemia. This includes primary myelofibrosis and secondary disease arising after polycythemia vera or essential thrombocythemia. A hematologist assesses blood counts, anemia severity, spleen enlargement, symptoms, and prior treatment before prescribing it. Ojjaara is not approved for every form of anemia or for unrelated blood disorders. Active infections and significant liver problems require evaluation before treatment begins.

How Should Ojjaara Be Taken?

The recommended Ojjaara dose is 200 mg orally once daily, with or without food. Tablets should be swallowed whole without crushing, cutting, or chewing. Patients with severe liver impairment generally begin at 150 mg once daily. Blood counts and liver tests are checked before treatment and monitored afterward. Dose interruptions or reductions can be required for adverse reactions. A missed dose should be skipped, with the next dose taken at the regularly scheduled time the following day.

What Are the Side Effects and Warnings of Ojjaara?

Common adverse effects include low platelet counts, bleeding, bacterial infections, fatigue, dizziness, diarrhea, and nausea. Serious risks include severe infections, hepatitis B reactivation, low neutrophil counts, liver injury, severe skin reactions, cardiovascular events, and blood clots. Symptoms can worsen after treatment interruption or discontinuation. Ojjaara can also harm an unborn baby. Clinicians monitor blood counts and liver function throughout treatment. New fever, unusual bleeding, chest pain, or jaundice requires prompt medical assessment.

Common Questions About Ojjaara

Is Ojjaara a treatment for myelofibrosis?

Yes. Ojjaara is approved for intermediate- or high-risk myelofibrosis in adults with anemia, including primary and specified secondary forms.

Can Ojjaara help with anemia?

Yes. Ojjaara affects JAK signaling and ACVR1-related hepcidin regulation, which can improve anemia-related outcomes in some patients with myelofibrosis.

How often is Ojjaara taken?

Ojjaara is generally taken once daily at 200 mg. Patients with severe liver impairment may require a lower starting dose.

Can Ojjaara increase infection risk?

Yes. Ojjaara can increase the risk of infections, including serious bacterial infections and hepatitis B reactivation. Clinicians assess infection history and monitor patients during treatment.

References

DailyMed - OJJAARA (momelotinib) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a672fd1-eb7b-4aa9-9b23-845e4b5dc400. Date Accessed October 22, 2026.

Momelotinib. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK601410/. Date Accessed October 22, 2026.

Momelotinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623053.html. Date Accessed October 22, 2026.

Momelotinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/25062766. Date Accessed October 22, 2026.

Momelotinib Dihydrochloride Monohydrate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/momelotinib-dihydrochloride-monohydrate. Date Accessed October 22, 2026.